Organization (Academic)
UNIVERSITY OF WARWICK
ClinicalTrials.gov lists UNIVERSITY OF WARWICK as lead sponsor of 26 trials. It has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers UNIVERSITY OF WARWICK: 26 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (107)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 6 |
| Diabetes Mellitus | 6 |
| Hypertension | 5 |
| Breast Neoplasms | 4 |
| Obesity | 4 |
Showing 5 of 107 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 6 |
| 2021 | 8 |
| 2020 | 13 |
| 2019 | 7 |
| 2018 | 6 |
| 2017 | 5 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: none of the 26 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| peri-articular infiltration | 1 |
| Femoral Nerve Block | 1 |
| CETUXIMAB | 1 |
| CISPLATIN | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 57% hit target (n=7) | 33% on time (n=9) |
Journals published in (95)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 16 |
| Trials | 7 |
| Critical care (London, England) | 6 |
| Blood | 5 |
| Early human development | 4 |
Showing 5 of 95 journals.
Organization relationships (49)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of London | Co sponsors trial with | 5 |
| University of Birmingham | Co sponsors trial with | 3 |
| University of Leeds | Co sponsors trial with | 3 |
| University Hospitals Coventry and Warwickshire NHS Trust | Co sponsors trial with | 3 |
| University of Edinburgh | Co sponsors trial with | 2 |
Showing 5 of 49 relationships.
Latest dated events (81)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 81 events.
Biomarker capability evidence (75)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
| LIAS | Trial sponsor | Named in trial inclusion criteria |
| NBN | Trial collaborator | Named in trial inclusion criteria |
| NMS | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 75 evidence rows.
Biomarkers this organization publishes on (591)
Shown in this order: most publications first.
Showing 5 of 591 biomarkers.
On Scientist.com
UNIVERSITY OF WARWICK is listed as a research supplier in the Scientist.com network.
Service areas
University of Warwick focuses on research.
- Website
- www2.warwick.ac.uk
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with University of Warwick on Scientist.com
For prices, more details, or to contact University of Warwick, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.